Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CAV1
REST API REST API
Homo sapiens
CAV1 is differentially expressed in 312 experiments: 193 organism parts: lung, bone marrow, ... (191 more);, 274 disease states: normal, glioblastoma, ... (272 more);, 113 cell types 577 cell lines 35 compound treatments and 70 other conditions.
Synonyms CAV
Orthologs cav1 (Danio rerio)   CAV1_BOVIN (Bos taurus)   F6YRU0_CIOIN (Ciona intestinalis)   Cav1 (Mus musculus)   F1NTW2_CHICK (Gallus gallus)   Cav1 (Rattus norvegicus)   cav1 (Xenopus laevis)   CAV1_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term focal adhesion, cytosol, plasma membrane, protein localization, negative regulation of JAK-STAT cascade, endoplasmic reticulum, protein binding, flagellum, cytoplasm, intracellular, syntaxin binding, cell cortex, negative regulation of cell proliferation, protein complex, negative regulation of signal transduction, Golgi membrane, protein homooligomerization, kinase binding, Golgi apparatus, MAPKKK cascade, structural molecule activity, lipid particle, maintenance of protein location in cell, receptor binding, blood coagulation, membrane raft, response to hypoxia, membrane fraction, cholesterol binding, soluble fraction, basolateral plasma membrane, protein oligomerization, response to nutrient, cholesterol homeostasis, triglyceride metabolic process, cellular calcium ion homeostasis, microtubule polymerization, regulation of smooth muscle contraction, integral to plasma membrane, positive regulation of microtubule polymerization, negative regulation of BMP signaling pathway, positive regulation of endocytosis, peptidase activator activity, lipid storage, endosome, response to drug, cytoplasmic vesicle, perinuclear region of cytoplasm, apical plasma membrane, integral to membrane of membrane fraction, negative regulation of MAP kinase activity, calcium ion transport, cholesterol transport, basal plasma membrane, negative regulation of transcription from RNA polymerase II promoter, cell surface, negative regulation of MAPKKK cascade, response to gamma radiation, skeletal muscle tissue development, response to mechanical stimulus, calcium ion homeostasis, caveola, mitochondrion, vesicle organization, negative regulation of cytokine-mediated signaling pathway, positive regulation of peptidyl-serine phosphorylation, cholesterol efflux, negative regulation of protein binding, regulation of peptidase activity, leukocyte migration, lactation, response to calcium ion, response to progesterone stimulus, regulation of nitric-oxide synthase activity, inactivation of MAPK activity, negative regulation of tyrosine phosphorylation of Stat5 protein, membrane depolarization, mammary gland development, positive regulation of canonical Wnt receptor signaling pathway, positive regulation of anti-apoptosis, response to estrogen stimulus, vasculogenesis, protein complex scaffold, negative regulation of nitric oxide biosynthetic process, positive regulation of calcium ion transport into cytosol, regulation of blood coagulation, interspecies interaction between organisms, vasoconstriction, SNARE binding, positive regulation of signal transduction, acrosomal membrane, negative regulation of peptidyl-serine phosphorylation, negative regulation of epithelial cell differentiation, nitric oxide homeostasis, mammary gland involution, positive regulation of metalloenzyme activity, T cell costimulation, regulation of fatty acid metabolic process, cytosolic calcium ion homeostasis, negative regulation of canonical Wnt receptor signaling pathway, caveola assembly, cellular response to starvation, response to glucocorticoid stimulus, negative regulation of endothelial cell proliferation, nitric-oxide synthase binding, positive regulation of vasoconstriction, nitric oxide metabolic process, endocytic vesicle membrane, positive regulation of peptidase activity, receptor internalization involved in canonical Wnt receptor signaling pathway
InterPro Term Caveolin
UniProt Accession Q2TNI1, C9JKI3, Q03135, E9PCT5, F8WDM7
Gene-Disease Assocation LIPODYSTROPHY, CONGENITAL GENERALIZED, TYPE 3; CGL3
Search EB-eye ENSG00000105974
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-6573, E-GEOD-1577, E-GEOD-7224, E-GEOD-3526, ... (31 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-19397, ... (40 experiments)

Factor Value U/D Experiments
BT474
3
E-MTAB-37, E-MEXP-440, E-MTAB-62
Jurkat
3
E-GEOD-1880, E-MTAB-62, E-MEXP-2197
MCF-7
3
E-GEOD-3529, E-GEOD-20081, E-GEOD-19639
A549
2
E-GEOD-3202, E-GEOD-6013
AGS
2
E-GEOD-15460, E-MTAB-37
HCC1937
2
E-MTAB-37, E-MTAB-62
571 more value(s).


Cell type

studied in E-MEXP-1121, E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, ... (50 experiments)

Factor Value U/D Experiments
endothelial cell
1
3
E-GEOD-96, E-GEOD-19240, E-GEOD-3920, E-GEOD-3998
human embryonic stem cell
2
E-GEOD-20033, E-GEOD-18265
epithelial cell
1
2
E-GEOD-3868, E-MEXP-1327, E-MEXP-1121
stromal cell
1
2
E-GEOD-1460, E-MEXP-1327, E-MEXP-1121
basaloid epithelial cell
1
E-GEOD-3868
primary blood vessel endothelial cell
1
E-MEXP-66
107 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-1577, E-TABM-15, E-GEOD-16363, E-MTAB-62, ... (72 experiments)

Factor Value U/D Experiments
glioblastoma
6
E-GEOD-4290, E-MTAB-62, E-GEOD-6014, E-MTAB-37, E-GEOD-4412, ... (6 experiments)
control
5
E-GEOD-21912, E-GEOD-3185, E-GEOD-20295, E-GEOD-20602, E-GEOD-16363 ... (5 experiments)
prostate carcinoma
5
E-MTAB-62, E-GEOD-3868, E-MEXP-2034, E-TABM-26, E-GEOD-96 ... (5 experiments)
lung adenocarcinoma
4
E-MTAB-62, E-MTAB-37, E-GEOD-2514, E-MEXP-231
colon carcinoma
3
E-MTAB-62, E-MTAB-57, E-MTAB-37
Duchenne muscular dystrophy
2
E-GEOD-3307, E-GEOD-1004
268 more value(s).


Compound treatment

studied in E-GEOD-4668, E-GEOD-5741, E-GEOD-15205, E-TABM-782, E-GEOD-697, ... (22 experiments)

Factor Value U/D Experiments
none
1
7
E-TABM-782, E-GEOD-4668, E-GEOD-412, E-GEOD-5824, E-MEXP-1958, ... (8 experiments)
unknown
1
E-GEOD-7307
5-aza-2'-deoxycytidine + trichostatin A
2
1
E-MEXP-1269
heregulin
1
E-GEOD-6462
actinomycin D
1
E-GEOD-6400
bacterial endotoxin
1
E-GEOD-3284
29 more value(s).


Age at diagnosis

studied in E-GEOD-3494, E-GEOD-4922

Factor Value U/D Experiments
86
1
1
E-GEOD-3494
86 years
1
E-GEOD-4922


Age at onset
studied in E-GEOD-21521

Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-TABM-325, E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, ... (8 experiments)

Clinical info
studied in E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, E-GEOD-19246, ... (9 experiments)

Clinical treatment
studied in E-GEOD-5377, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-5999, E-GEOD-20033, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-22544, E-GEOD-3325, E-MTAB-69, ... (8 experiments)

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-1643

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (8 experiments)

Genotype
studied in E-GEOD-2152, E-MEXP-1437, E-MEXP-1996, E-GEOD-17476, E-GEOD-22593, ... (17 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-21612, E-GEOD-20540, E-GEOD-10315, E-TABM-440, ... (16 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-974, E-GEOD-1926, E-MEXP-1648, ... (31 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12254, E-GEOD-9723, E-MEXP-561, E-GEOD-17400 ... (5 experiments)

Injury
studied in E-GEOD-5372

Karyotype
studied in E-GEOD-22056, E-GEOD-12662

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Phenotype
studied in E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, E-GEOD-17636, E-GEOD-2487 ... (5 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19246

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-19330, E-GEOD-18791

RNAi
studied in E-MEXP-1509, E-GEOD-1676, E-MEXP-101, E-MEXP-548, E-GEOD-3697 ... (5 experiments)

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-MEXP-70

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-19069, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-4883, E-GEOD-20114

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-13818, E-GEOD-15799, E-GEOD-12198 ... (5 experiments)

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 00 005
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-3494, E-GEOD-1561, E-GEOD-4922, ... (6 experiments)

Processing time: 0.363 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM